Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK rearrange |
| Therapy | Ceritinib |
| Indication/Tumor Type | Cancer of Unknown Primary |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK rearrange | Cancer of Unknown Primary | sensitive | Ceritinib | Guideline | Actionable | Zykadia (ceritinib) is included in guidelines for patients with cancer of unknown primary harboring ALK rearrangements (PMID: 36563965, PMID: 30285222; ESMO.org). | detail... 30285222 36563965 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| ESMO Clinical Practice Guidelines | Full reference... | |
| (36563965) | Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Full reference... |
| (30285222) | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Full reference... |